ImmuCell Corporation (NASDAQ:ICCC) Sees Large Increase in Short Interest

ImmuCell Corporation (NASDAQ:ICCC) was the recipient of a large growth in short interest in the month of January. As of January 15th, there was short interest totaling 10,924 shares, a growth of 40.4% from the December 31st total of 7,780 shares. Currently, 0.1% of the company’s stock are sold short. Based on an average daily trading volume, of 27,377 shares, the short-interest ratio is currently 0.4 days. Based on an average daily trading volume, of 27,377 shares, the short-interest ratio is currently 0.4 days. Currently, 0.1% of the company’s stock are sold short.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in ImmuCell stock. Steadtrust LLC bought a new position in shares of ImmuCell Corporation (NASDAQ:ICCC) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 31,700 shares of the biotechnology company’s stock, valued at approximately $198,000. Steadtrust LLC owned approximately 0.35% of ImmuCell as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 13.47% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (d+)” rating on shares of ImmuCell in a research report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, ImmuCell has an average rating of “Sell”.

ImmuCell Stock Down 0.3%

ImmuCell stock traded down $0.02 during mid-day trading on Friday, reaching $6.02. The company’s stock had a trading volume of 8,934 shares, compared to its average volume of 24,867. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.76 and a current ratio of 4.21. ImmuCell has a 12 month low of $4.28 and a 12 month high of $7.60. The business’s 50 day simple moving average is $5.95 and its 200 day simple moving average is $6.10. The company has a market capitalization of $54.48 million, a price-to-earnings ratio of 23.15 and a beta of 0.18.

ImmuCell (NASDAQ:ICCC) last posted its quarterly earnings data on Thursday, November 13th. The biotechnology company reported ($0.02) EPS for the quarter. The business had revenue of $5.51 million for the quarter. ImmuCell had a return on equity of 8.00% and a net margin of 8.37%.

ImmuCell Company Profile

ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.